Biohaven could get up to $795M in epilepsy alliance with SK Bio
At the center of Biohaven’s agreement with SK Biopharmaceutical is the ion channel platform and the lead epilepsy candidate opakalim, for which Phase 2/3 data are expected later this year.
Biohaven could get up to $795M in epilepsy alliance with SK Bio Read More »
